MLYS - Mineralys Therapeutics, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $-0.57
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$52.00
DETAILS
HIGH:
$52.00
LOW:
$52.00
MEDIAN:
$52.00
CONSENSUS:
$52.00
UPSIDE:
73.56%
Market Cap:
1.99B
Volume:
768,359
Avg Volume:
1,313,908
52 Week Range:
8.241-47.65
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.51
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
51
IPO Date:
2023-02-10
EPS (TTM):
-3.66
P/E Ratio:
-3.36
Revenue (TTM):
N/A
Total Assets:
205.90M
Total Debt:
N/A
Cash & Equiv:
114.09M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-100.6%
Debt/Equity:
N/A
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-0.52 | $-0.66 | +21.2% | — | — | — |
| 2025-08-12 | $-0.66 | $-0.78 | +15.4% | — | — | — |
| 2025-05-12 | $-0.79 | $-1.02 | +22.5% | — | — | — |
| 2025-02-12 | $-0.98 | $-1.00 | +2.0% | — | — | — |
| 2024-11-11 | $-1.13 | $-0.83 | -36.1% | — | — | — |
| 2024-08-13 | $-0.83 | $-0.73 | -13.7% | — | — | — |
| 2024-05-09 | $-0.70 | $-0.68 | -2.9% | — | — | — |
| 2024-03-21 | $-0.61 | $-0.85 | +28.2% | — | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Net Income | (177.81M) | (71.90M) | (29.80M) | (19.41M) | (3.43M) |
| EPS | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Total Assets | 205.90M | 251.64M | 114.44M | 11.12M | 1.49M |
| Total Debt | 0 | 0 | 0 | 0 | 4.50M |
| Cash & Equivalents | 114.09M | 49.30M | 87.70M | 10.61M | 1.41M |
| Operating Cash Flow | (166.31M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| Free Cash Flow | (166.41M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| FCF per Share | -3.43 | -2.24 | -5.66 | -2.92 | -0.53 |
| Book Value | 191.26M | 241.15M | (52.27M) | (22.93M) | (3.60M) |
| Cash & ST Investments | 198.19M | 236.57M | 110.11M | 10.61M | 1.41M |
| ROC Equity | -0.93 | -0.30 | N/A | N/A | N/A |